Dr. Hoffman-Censits is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
201 N. Broadway
5th Floor
Baltimore, MD 21287Phone+1 410-955-8964Fax+1 410-955-6301- Is this information wrong?
Education & Training
- Temple University HospitalFellowship, Hematology and Medical Oncology, 2006 - 2009
- Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2002 - 2006
- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2002
- Trinity CollegeB.S., Neuroscience, 1995
Certifications & Licensure
- VA State Medical License 2024 - 2026
- PA State Medical License 2002 - 2024
- MD State Medical License 2018 - 2024
- DC State Medical License 2018 - 2024
- DE State Medical License 2017 - 2019
- NJ State Medical License 2017 - 2019
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2011-2013
- Senior Achievement Award National Alumni Association, 1995
- Join now to see all
Clinical Trials
- Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Sep 26
- A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies Start of enrollment: 2009 Dec 11
- Tesetaxel for Previously Treated Patients With Bladder Cancer Start of enrollment: 2010 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- PET/Computed Tomography Transformation of Oncology: Kidney and Urinary Tract Cancers.Rathmell, W., Nimmagadda, S., Rowe, S., Oldan, J., Schroeder, J., Hoffman-Censits, J., Milowsky, M., Solnes, L., Gorin, M., Khandani, A.> ;PET Clinics. 2024 Apr 1
- Emerging Insights in Small-Cell Carcinoma of the Genitourinary Tract: From Diagnosis to Novel Therapeutic Horizons.Ruan, H., Huynh, M., Nadal Rios, R., Barata, P., Liao, R., Jang, A., Hoffman-Censits, J., Wei, S., Mian, O., Jang, A.> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2024 Jan 1
- 1 citationsThe JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma.Jean Hoffman-Censits, Petros Grivas, Thomas Powles, Jessica Hawley, Karin Tyroller, Sonja Seeberger, Silke Guenther, Natalia Jacob, Keyvan Tadjalli Mehr, Noah M Hahn> ;Future Oncology. 2024 Feb 1
- Join now to see all
Journal Articles
- Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen TherapiesDan TD, Eldredge-Hindy HB, Hoffman-Censits, J, Lin J, Kelly WK, Gomella LG, Lallas CD, Trabulsi EJ, Hurwitz MD, Dicker AP, Den RB, Am J Clin Oncol, 1/25/2015
- Perioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial CarcinomaHoffman-Censits, J. and Wong, Y, Clin Genitourin Cancer, 1/1/2015
- Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based chemotherapy in Muscle-invasive Bladder CancerPlimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, V..., Eur Urol, 1/1/2015
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Neoadjuvant chemotherapy (NAC) has no adverse effect on radical cystectomy (RC) or perioperative complications.Haseebuddin,M., Mehrazin, R., Trabulsi, E., Devarajan, K., Wong, Y., Hoffman-Censits, J., Lallas, C., Viterbo, R., Kutikov, A., Smaldone, M., Greenberg, R., Uzzo, R...., Journal of Urology; Society of Urologic Oncology Meeting Abstracts, 1/1/2015
- Phase I trial of weekly cabazitaxel with concurrent intensity-modulated radiation therapy (IMRT) and androgen deprivation therapy (ADT) for the treatment of high-risk ...Jianqing Lin, Robert Benjamin Den, Timothy Norman Showalter, Jean H. Hoffman-Censits, Monica McGuire, Brooke Kennedy, Mark Hurwitz, Edouard John Trabulsi, Costas D. La..., ASCO GU Meeting Abstracts, 1/1/2015
- Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer.Plimack ER, Dunbrack R, Brennan T, Andrake M, Zhou Y, Serebriiskii I, Dulaimi E, Hoffman-Censits J, Bilusic M, Wong Y, Kutikov A, Viterbo R, Greenberg RE, Chen D, Lall..., ASCO GU Meeting Abstracts, 1/1/2015
- Join now to see all
Lectures
- Atezolizumab (atezo) in special populations: Analyses from an expanded access program (EAP) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Bladder Cancer – evolving paradigms and immunotherapy.Albert Einstein Medical Center, Philadelphia, PA - 1/1/2015
- Update on Clinical Trials in Urothelial CarcinomasKing of Prussia, PA - 1/1/2015
- Join now to see all
Press Mentions
- Improved Patient Selection Needed to Optimize Expanding Options in Bladder CancerOctober 27th, 2017
- Atezolizumab Update Affirms Activity in Bladder CancerJanuary 9th, 2016
- Combination Urothelial Cancer Treatment Nearly Doubles Patient Survival in International TrialMarch 8th, 2024
Hospital Affiliations
- Johns Hopkins HospitalBaltimore, Maryland
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: